Tobramycin eye drops

This product is suitable for local infection of the external eye and appendages caused by sensitive bacteria. This product belongs to the aminoglycoside antibiotics. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella; the antibacterial effect of this product on Pseudomonas aeruginosa is 3 to 5 times stronger than that of gentamicin, and Pseudomonas aeruginosa that is moderately sensitive to gentamicin is highly sensitive to this product. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are all resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins.

Tobramycin.

This product is a colorless or almost colorless clear solution.

This product is suitable for local infections of the external eye and its appendages caused by sensitive bacteria.

Drop into the eyelid. Mild and moderate infection: 1-2 drops at a time, once every 4 hours; severe infection: 2 drops at a time, once every hour.

Occasionally, local irritation symptoms may occur, such as burning or swelling of the eyelids, conjunctival erythema, etc.; allergic reactions are rare.

Patients who are allergic to this product or other aminoglycoside antibiotics are contraindicated.

Precautions for children: Because this product has potential nephrotoxicity and ototoxicity, it should be used with caution in children. Precautions for pregnancy and lactation: Pregnant women: Reproductive experiments on three animals using tobramycin at a dose 33 times that of human systemic medication did not show decreased fertility or fetal damage. However, there is currently no conclusive clinical research report on pregnant women, so pregnant women should only use this product when it is really necessary. Lactating women: Because of the potential for adverse reactions during breastfeeding, it is recommended to stop breastfeeding or stop taking the drug based on clinical considerations. Precautions for the elderly: Because this product has potential nephrotoxicity and ototoxicity, it should be used with caution in elderly patients.

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used in combination with other aminoglycosides. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when used locally or systemically in sequence, it can increase ototoxicity and nephrotoxicity, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used in combination with cephalothin. 4. This product combined with polymyxins can increase nephrotoxicity and neuromuscular blocking effects. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs or used sequentially to avoid nephrotoxicity or ototoxicity.

Keep away from light and store in a sealed container.

8ml:24mg

24 months

Jiangsu Xiangrui Pharmaceutical Co., Ltd.

• Founded in:

  2003-12-18

• Address:

  Xiangshui County West (inside the former pharmaceutical factory)

• Tax NO.:

  91320921757309253K

• Registered Funds:

  20 million yuan

• Email:

  Log in to view